Type I allergic reaction to rituximab upon first lifetime exposure: a case report

Overview of attention for article published in Allergy, Asthma & Clinical Immunology, June 2020

Altmetric Badge

About this Attention Score

Above-average Attention Score compared to outputs of the same age (53rd percentile)
Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter: 9 X users

facebook: 1 Facebook page

Citations

dimensions_citation: 8 Dimensions

Readers on

mendeley: 14 Mendeley

Summary X Facebook Dimensions citations

So far, Dimensions has found 8 publications that cite this research output.

8

The most recent citing publications are shown below. View all 8 publications that cite this research output on Dimensions.

The Efficacy of Bepotastine Besilate Compared With Hydroxyzine Pamoate for Preventing Infusion Reactions to the First Dose of Rituximab in Patients With Non-Hodgkin Lymphoma: Protocol for a Phase II, Double-Blind, Multicenter Randomized Trial

Article in JMIR Research Protocols (February 2024)

The Efficacy of Bepotastine Besilate Compared With Hydroxyzine Pamoate for Preventing Infusion Reactions to the First Dose of Rituximab in Patients With Non-Hodgkin Lymphoma: Protocol for a Phase II, Double-Blind, Multicenter Randomized Trial (Preprint)

Preprint in JMIR Preprints (November 2023)

Immediate hypersensitivity reactions to antineoplastic agents – A practical guide for the oncologist

Article in Cancer Treatment Reviews (April 2023)

This page shows the most recent citations of this research output.

Click here to find out how to access more activity.